A new health and economic model clearly shows why it’s imperative that food manufacturers reduce the amount of added sugar in their products.
Explore This Research Lab
OverviewHepatorenal syndrome is complicated disease that results from a number of factors related to kidney and liver health. As a clinical and translational researcher, I work to understand current treatments for patients with this disease through two main pathways. First, we perform large epidemiologic analyses to optimize current therapies (such as vasoconstrictive medications, dialysis, or transjugular intrahepatic portosystemic shunt [TIPS] placement). Second, we are exploring new mechanisms and treatments for hepatorenal syndrome by examining regulators of vascular inflammation and endothelial cell dysfunction (such as Angiopoietin/Tie2 signaling). We have a growing biorepository of blood and urine samples of patients with hepatorenal syndrome that we use to improve testing and treatment of this population. We have ongoing collaborations between research centers in Nephrology and Hepatology at MGH, Beth Israel Deaconess Medical Center, and the Liver Unit at the University of Barcelona.
- Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. American Journal of Kidney Diseases. 2016; 68: 381-91.
- Allegretti AS, Vela Parada X, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of patients with cirrhosis and acute kidney injury who initiate renal replacement therapy. Clinical Journal of the American Society of Nephrology. 2018; 13(1):16-25.
- Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi, M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT. Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology. 2019; 69(2):729-741.
- Director of Critical Care Nephrology - Department of Medicine
- Assistant Professor of Medicine - Harvard Medical School
- Aug | 13 | 2021
In this interview, Kerry Reynolds, MD chats with Meghan Sise, MD, director of onconephrology at Mass General Hospital, to learn more about how immune checkpoint inhibitor (ICI) therapy affects kidney function.
- Press Release
- Jul | 8 | 2021
Las puntuaciones de riesgo genético podrían mejorar la identificación clínica de los pacientes con mayor riesgo de infarto
Un equipo descubrió recientemente que la aplicación de la PRS puede identificar a los pacientes de riesgo que actualmente no se identifican mediante las evaluaciones clínicas estándar.
- Press Release
- Jun | 7 | 2021
Automated emails and letters that provide personalized feedback related to cafeteria purchases at work may help employees make healthier food choices.
- Staff Story
- Nov | 17 | 2020
Winfred W. Williams, MD, has been named a deputy editor of The New England Journal of Medicine. Williams, who is associate chief of the Division of Nephrology, becomes the first African American to serve in that role.
- Press Release
- Sep | 2 | 2020
Mass General study demonstrates that kidneys infected with hepatitis C can be safely transplanted into healthy recipients
Mass General study demonstrates that kidneys infected with hepatitis C can be safely transplanted into healthy recipients.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.